Previous close | 0.0560 |
Open | 0.0600 |
Bid | 0.0550 x N/A |
Ask | 0.0560 x N/A |
Day's range | 0.0560 - 0.0610 |
52-week range | 0.0550 - 0.2031 |
Volume | |
Avg. volume | 678,256 |
Market cap | 24.927M |
Beta (5Y monthly) | 0.96 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1400 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 0.70 |
SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to commence its First-In-Human Phase I study in Australia for the Company’s therapy for patients with PDL1-positive non-small cell lung cancer (NSCLC). The dose escalation trial of RAD204, which targets PDL1-p
Radiopharm Theranostics ( ASX:RAD ) Full Year 2023 Results Key Financial Results Net loss: AU$34.6m (loss widened by...
Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancerSYDNEY, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce an expanded agreement with TerThera to supply the Company with Terbium-161 (Tb-161). The Tb-161 isotope will be linked to a proprietary monoc